In an op-ed for The Hill, Professor Neeraj Sood writes that until legislators and regulators understand where the profits are flowing in the prescription drug distribution system, bills to control prices risk being ineffective.
The CBO estimated that the Pelosi drug pricing reform legislation proposed would save Medicare $345 billion over seven years. It failed to look at the long-term effect on new drug discovery and the impact on population health.
Helping people benefit from the programs for which they are eligible could have a significant impact on the share of Americans with health coverage, possibly making the idea of automatic enrollment into coverage attractive across the political spectrum.
Do the clinical gains offered by these drugs in treating specific cancer indications justify the price increases? Schaeffer Center researchers Alice Chen and Dana Goldman explore how we might measure the value of these drugs.